Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE)
Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results
Seeking Alpha / 3 minutes from now 1 Views
Comments